Production (Stage)
Silence Therapeutics plc
SLN
$5.19
$0.193.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.10% | 1,180.55% | -58.05% | -93.38% | 13.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.10% | 1,180.55% | -58.05% | -93.38% | 13.67% |
| Cost of Revenue | -98.07% | 57.35% | 77.41% | -6.09% | -49.14% |
| Gross Profit | -99.32% | 4,086.30% | -240.83% | -132.77% | 55.30% |
| SG&A Expenses | 15.81% | 30.94% | 16.13% | 4.19% | -15.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.73% | 129.36% | 57.04% | -7.26% | -34.23% |
| Operating Income | -733.77% | 209.44% | -82.40% | -61.18% | 79.08% |
| Income Before Tax | -1,279.59% | 334.35% | -190.74% | -46.35% | 86.56% |
| Income Tax Expenses | -- | -2.40% | -34.11% | -17.70% | 108.14% |
| Earnings from Continuing Operations | -1,134.00% | 159.17% | -236.52% | -50.79% | 81.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,134.00% | 159.17% | -236.52% | -50.79% | 81.34% |
| EBIT | -733.77% | 209.44% | -82.40% | -61.18% | 79.08% |
| EBITDA | -772.26% | 214.46% | -83.28% | -61.80% | 79.89% |
| EPS Basic | -1,048.48% | 148.75% | -166.71% | -16.67% | 84.73% |
| Normalized Basic EPS | -1,184.35% | 293.13% | -130.47% | -13.24% | 89.00% |
| EPS Diluted | -1,048.48% | 148.75% | -166.71% | -16.67% | 84.73% |
| Normalized Diluted EPS | -1,184.35% | 293.13% | -130.47% | -13.24% | 89.00% |
| Average Basic Shares Outstanding | 7.43% | 21.34% | 26.16% | 29.24% | 22.18% |
| Average Diluted Shares Outstanding | 7.43% | 21.34% | 26.16% | 29.24% | 22.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |